BioCardia, Inc. BCDA

BCDA Company Overview

BioCardia, Inc. is a U.S.-based biotechnology and regenerative medicine company focused on developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases. The company operates primarily within the biopharmaceutical, medical device, and regenerative medicine industries, with a strategic emphasis on therapies intended to repair damaged tissue and improve functional outcomes in patients with chronic heart failure and ischemic cardiovascular conditions. BioCardia combines therapeutic biologics with proprietary delivery technologies designed to improve the precision and effectiveness of cell-based treatments.

The company’s principal revenue drivers historically have included clinical-stage therapeutic development, licensing arrangements, and sales or partnerships associated with its proprietary delivery catheter platforms. BioCardia is particularly known for its lead therapeutic candidates targeting heart failure and myocardial ischemia, including programs based on autologous and allogeneic cell therapies. Its strategic positioning is supported by an integrated platform that combines biologic therapeutics with minimally invasive delivery systems, differentiating the company from developers focused solely on drug or device technologies. Founded in 2002 and headquartered in California, BioCardia evolved from a cardiovascular device-focused business into a regenerative medicine company centered on advanced cellular therapeutics and translational clinical development.